Member Info for Rocket79

Its around 60 %. Grizzly caused the dip and closed their short only after a few days. Share price should recover from here.

JPMorgan now holds 6.15% of Trustpilot's voting rights (up from their previous position of 5.96%).

​Total Voting Rights: They now control approximately 24.69 million voting rights.

​Timing: Crucially, the threshold was crossed on Monday, December 8, just as the stock was recovering from the short attack lows.

Why this matters

​This is a significant "Institutional Vote of Confidence" that parallels the "Insider Vote of Confidence" (Director buying) I mentioned earlier.

​Smart Money is Buying: While retail investors may have been panic-selling on the Grizzly Research news, one of the world's largest asset managers was actively accumulating more shares during the volatility.

​Confirmation: This confirms that the "dip" was viewed by major institutions as a buying opportunity, not a reason to exit.

Trustpilot presents a compelling buy case driven by a powerful network effect that has just survived a major stress test. The company’s pivot to sustainable profitability and free cash flow generation is now further validated by the failure of the recent short attack by Grizzly Research. With Grizzly reportedly closing its short position just days after the initial drop, the market has effectively rejected the "bear thesis," clearing a significant overhang on the stock. This rapid capitulation by the short seller—combined with immediate insider buying from the CEO and Chair—signals extreme management confidence and suggests the dip was a liquidity event rather than a fundamental break, offering an attractive entry point into a market leader with massive US growth potential.

Shorts also increased their stake allowing Grizzly to exit. Grizzly even done the dirty on other shorts as they will also need to close now as report is not worth paper it was written on. If it was Grizzly would not have closed their short.

Agree they closed their short so had no conviction in their argument. Buy for a rise into results....

Bloom down and i expect this to be down as markets take in the hawkish cut. Where is the bottom??

Not true sorry.

Patience will be rewarded. Doosan update on royalties expected hopefully before year end.

Those holding will be rewarded. Data centres need energy... some 12 month price targets below.

Price targets....

Berenberg Buy 530p November 19, 2025 Raised from a prior target of 300p.

UBS Buy 570p November 13, 2025 Maintained previous high target.

Jefferies Buy 460p November 7, 2025 Reiteration of a previous "Buy" call.

Goldman Sachs Buy 530p November 4, 2025

Expect this to finish above 360p today...

Trustpilot raised to Overweight at Morgan Stanley. target price of 275p

Both shorts closing and investors buying. Directors buys also give me confidence.

FT Article mentions...

Roger Phillips, a software analyst at Investec, said there “is nothing here worth addressing” in the report.

This is a buy for me.

Conference yesterday was very informative. Another one today

· 37th Annual Piper Sandler Healthcare Conference, New York

Format: Analyst led fireside chat and one-on-one and group investor meetings

Date: Wednesday, 3 December

Fireside chat time: 12:30pm EST (5:30pm GMT)

Webcast: click here to register

· Berenberg European Conference, Windsor

Format: Analyst led fireside chat and one-on-one and group investor meetings

Date: Thursday, 4 December

Fireside chat time: 3:30pm GMT

Share price will reflect true value as bears are being proved wrong because the "niche research tool" thesis has been dismantled by the explosive adoption of the high-throughput PromethION platform. Doubters argued that Oxford Nanopore would remain stuck in low-volume academic labs, yet PromethION sales surged approximately 60% in the first half of 2025.

This confirms that industrial and commercial customers—who sign larger, stickier contracts—are actively replacing legacy technology (like Illumina) with Nanopore for production-scale sequencing. The company’s confirmation in November 2025 that full-year revenue will hit the top end of guidance (23% growth) directly contradicts the "growth slowdown" narrative, proving that demand is accelerating despite a tough macro environment.

​Furthermore, the "cash burn" fear is being invalidated by a tangible shift toward high-quality, recurring clinical revenue for 2026. Unlike volatile academic grants, the new growth drivers are multi-year infrastructure projects, such as the UK Biobank contract (which ramps fully in 2026) and the strategic biosecurity partnership with the UK government. These deals lock in revenue visibility that the bears claimed didn't exist. With the company successfully narrowing its EBITDA losses and maintaining gross margins around 59%, the path to profitability is now driven by execution rather than speculation, leaving short sellers with a shrinking window to justify their pessimism.

Totally agree, there was a large buyer loading up yesterday at 138p also. No smoke without fire.

With todays news the announcement of new CEO could be imminent as investor presentations are going ahead begining of December. This will be a share price catalyst....

The recent price action and significant surge trading volume are technically suggestive of an impending takeover. Given that CEO Gordon Sanghera's anti-takeover share has lapsed, the company is now widely considered 'exposed' to a bid from a large strategic player like Danaher or Thermo Fisher Scientific. This increased buying activity—evidenced by sharp share price rises and transaction volume spikes—reflects the market swiftly pricing in the takeover premium that an acquirer would have to offer above the current depressed valuation to secure the company's revolutionary nanopore technology. In essence, the chart's signal is of traders and arbitrageurs racing to lock in the expected uplift before an official M&A announcement is made.

With the significant increase involume and share price rise, it does seem we could be in for some exciting news....

Could you provide a link please

Have you a link please. Any take over will be above 300p imo